Advent Access is a medical technology startup focused on end-stage renal disease management. A Stanford StartX company and spin-off from A*STAR, Advent’s mission is to pioneer innovations to significantly reduce dialysis cost and restore quality of life for kidney failure patients. The company’s first product is the av-Guardian™ - an award-winning implant technology that aims to improve vascular access reliability, enable less-painful self-cannulation and, in the long run, potentially reduce vascular access related hospitalizations. The av-Guardian™ forms a key component of Advent Access’ dialysis-machine agnostic platform to empower patients to perform hemodialysis independently, safely and more affordably - at home or in novel care environments.
The startup is founded with an executive management and investors with a collective experience of pioneering more than ten startups in medtech and a track record of successful IPOs and exits. The company has raised >$5.6M of private investments and research grants to date.
For more information, please refer to www.adventaccess.com
Company Details
- Founded
- 2015
- Address
- 3 Tuas Lane, Singapore,singapore 638612,singapore
- Industry
- Medical Device
- Website
- http://adventaccess.com
- HQ
- Singapore, Singapore
Advent Access Questions
Advent Access's website is http://adventaccess.com
Advent Access's LinkedIn profile is https://sg.linkedin.com/company/adventaccess
Advent Access's industry is
Medical Device
Advent Access's top competitors are
Intraoperative Neurophysiology Society Of Asia-Pacific,
Innomed Accelerator,
Rmc,
Lumos Health Advisory,
Btl Aesthetics And Body,
Wikkon,
Altumv Technology,
Biomed+,
Archmed Pte. Ltd.,
Abm.
Advent Access's categories are Medical Device
Advent Access's founding year is 2015
